Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.
Histology
Hydrophilic
Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors
Lipophilic
Ovarian cancer risk
Review
Statin
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
01
2020
accepted:
07
07
2020
pubmed:
21
7
2020
medline:
1
12
2020
entrez:
21
7
2020
Statut:
ppublish
Résumé
The link between lipid-stabilizing medications and epithelial ovarian carcinogenesis is incompletely understood. Statins may reduce ovarian cancer risk, but results are inconclusive. We conducted a systematic review and meta-analysis of studies reporting associations between statin use and ovarian cancer risk in PubMed. Summary risk ratios (RRs) and confidence intervals (CIs) were calculated. Subgroup analyses by cancer histotype, statin class (lipo- or hydrophilic) and duration of statin use were conducted. Use of individual statins in populations was assessed to determine population-specific differences in statin types. Nine studies with 435,237 total women were included (1 randomized controlled trial (RCT); 4 prospective; 4 case-control). Statin use was associated with a reduced risk of ovarian cancer (RR 0.87, 95% CI 0.74-1.03) and risk was significantly reduced in populations with low pravastatin use (RR 0.83, 95% CI 0.70-0.99). Risk estimates varied by statin class (3 studies; lipophilic: RR 0.88, 95% CI 0.69-1.12; hydrophilic: RR 1.06, 95% CI 0.72-1.57) and cancer histotype (3 studies; serous: RR 0.95, 95% CI 0.69-1.30; clear cell: RR 1.17, 95% CI 0.74-1.86). Long-term use was associated with a reduced risk of ovarian cancer (RR 0.77, 95% CI 0.54-1.10) that further reduced when pravastatin use was low (RR 0.68, 95% CI 0.46-1.01). Between-study heterogeneity was high overall and in subgroups (I Statins may be associated with a reduced risk of ovarian cancer, but the effect likely differs by individual statin, duration of use and cancer histotype. Additional well-powered studies are needed to elucidate important subgroup effects.
Identifiants
pubmed: 32685996
doi: 10.1007/s10552-020-01327-8
pii: 10.1007/s10552-020-01327-8
pmc: PMC7484024
mid: NIHMS1613201
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-879Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Références
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
pubmed: 10469746
Anticancer Agents Med Chem. 2014 Jun;14(5):706-12
pubmed: 24295174
Eur J Clin Pharmacol. 2014 May;70(5):557-64
pubmed: 24463538
J Natl Cancer Inst. 2014 Feb;106(2):djt431
pubmed: 24503200
Trends Pharmacol Sci. 1998 Jan;19(1):26-37
pubmed: 9509899
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Nat Rev Cancer. 2005 Dec;5(12):930-42
pubmed: 16341084
Cell Death Dis. 2019 Apr 11;10(4):327
pubmed: 30975976
N Engl J Med. 1996 Oct 3;335(14):1001-9
pubmed: 8801446
Curr Mol Pharmacol. 2017;10(2):77-85
pubmed: 26758953
J Womens Health Gend Based Med. 2001 Dec;10(10):971-81
pubmed: 11788107
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):
pubmed: 28698192
Int J Cancer. 2019 Mar 1;144(5):991-1000
pubmed: 30006925
Glycobiology. 2016 Feb;26(2):166-80
pubmed: 26405105
Epidemiol Rev. 1987;9:1-30
pubmed: 3678409
J Cell Mol Med. 2010 May;14(5):1180-93
pubmed: 19432822
Int J Epidemiol. 2013 Apr;42(2):579-89
pubmed: 23569193
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
J Lipid Res. 2015 Dec;56(12):2381-92
pubmed: 26486974
Int J Gynecol Cancer. 2019 Jan;29(1):140-146
pubmed: 30640696
Lancet. 2016 Mar 5;387(10022):945-956
pubmed: 26707054
BMJ Open. 2015 Mar 06;5(3):e007207
pubmed: 25748418
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62
pubmed: 23404857
Cancer Causes Control. 2013 May;24(5):989-1004
pubmed: 23456270
Gynecol Oncol. 2013 Sep;130(3):615-9
pubmed: 23718932
Gynecol Oncol. 2015 Mar;136(3):542-8
pubmed: 25528498
Int J Oncol. 2003 Oct;23(4):1173-8
pubmed: 12964001
Cancer Causes Control. 2018 Jan;29(1):13-24
pubmed: 29197994
Br J Cancer. 2015 Jan 6;112(1):157-61
pubmed: 25393364
Oncotarget. 2017 Aug 7;8(42):72147-72156
pubmed: 29069775
PLoS One. 2018 May 15;13(5):e0197422
pubmed: 29763460
Pharmacotherapy. 2012 Jan;32(1):1-6
pubmed: 22392823
Gynecol Oncol. 2014 Jun;133(3):647-55
pubmed: 24736024
Am J Epidemiol. 2017 Jan 1;185(1):8-20
pubmed: 27941069
Lipids Health Dis. 2015 Jul 15;14:72
pubmed: 26174150
Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36
pubmed: 17944002
Lancet. 2002 Nov 23;360(9346):1623-30
pubmed: 12457784
BMC Cancer. 2019 Jul 24;19(1):730
pubmed: 31340777
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Cancer Causes Control. 2009 Jul;20(5):609-16
pubmed: 19043788
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
NCHS Data Brief. 2014 Dec;(177):1-8
pubmed: 25536410
Am J Cancer Res. 2018 May 01;8(5):778-791
pubmed: 29888102
Front Oncol. 2019 May 14;9:348
pubmed: 31139559
BJOG. 2018 Jul;125(8):1001-1008
pubmed: 29412502
JAMA Cardiol. 2017 Jan 1;2(1):56-65
pubmed: 27842171
Gynecol Oncol. 2018 Mar;148(3):540-546
pubmed: 29422345
Br J Cancer. 2018 Oct;119(7):847-854
pubmed: 30293997
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2016 Jul 26;7(30):47343-47365
pubmed: 27329838
Br J Cancer. 2004 Feb 9;90(3):635-7
pubmed: 14760377
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Oncologist. 2006 Mar;11(3):306-15
pubmed: 16549815
Methods Enzymol. 2014;542:1-23
pubmed: 24862258
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1897-8
pubmed: 16103434